Stocks · News reference
Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over losses of $(1.99) per
8-K filing — Dogwood Therapeutics, Inc. (DWTX)
Filed: 2026-08-13 AccNo: 0001104659-26-095512 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits